Norepinephrine dosing in France: Time to move forward!

Area of Science:

• Pharmacology and Critical Care Medicine

Background:

• Norepinephrine is a vital first-line vasopressor for acute cardio-circulatory failure.
• Accurate norepinephrine dosing is critical for patient assessment, comparative studies, and targeted interventions.
• Variations in norepinephrine product formulations exist across different countries and manufacturers.

Purpose of the Study:

• To highlight discrepancies in norepinephrine dosing practices.
• To explain how salt formulations influence total product weight while norepinephrine base remains constant.
• To propose recommendations for improving clinical practices and inter-study comparisons.

Main Methods:

• Review of existing literature on norepinephrine formulations and dosing.
• Analysis of the impact of different salt forms on drug concentration.
• Synthesis of evidence to identify risks associated with formulation variability.

Main Results:

• Norepinephrine products are formulated as salts, affecting total weight but not the active norepinephrine base.
• These formulation differences lead to significant variations in administered doses and clinical practices.
• Lack of standardization poses risks in patient evaluation, treatment, and research comparability.

Conclusions:

• Differences in norepinephrine salt formulations necessitate careful attention to dosing.
• Standardization of practices is essential to mitigate risks and ensure consistent patient care.
• Recommendations are provided to address these variations at clinical and research levels.